Skip to main content

Advertisement

Table 2 Liver steatosis and fibrosis of patients at baseline and after 3 month (Mean values and standard deviations)

From: Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial

Characteristics Baseline Mean ± SD After 3 month Mean ± SD P* Change Mean ± SD P
Fibrosis (kPa)
Cit 5.85 ± 1.71 5.84 ± 2.00 0.44 − 0.21 ± 1.18 0.8
Placebo 6.27 ± 2.08 6.12 ± 1.81 0.15 − 0.43 ± 1.15  
Steatosis grade (0/1/2/3)
Cit 2.86 ± 0.35 2.44 ± 0.85 0.04 − 0.44 ± 0.85 0.8
Placebo 2.62 ± 0.66 2.38 ± 0.88 0.13 − 0.37 ± 0.95  
Steatosis (dB/m)
Cit 320.8 ± 29.6 304.5 ± 39.1 0.127 − 16.33 ± 43.18 0.97
Placebo 315.5 ± 36.8 299.6 ± 45.7 0.171 − 15.87 ± 44.19  
  1. * P values indicate comparison within groups
  2. P values indicate comparison between the changes of each variable between two groups
  3. According to ultrasound exam